Key facts
- This page summarizes Cam Gallagher's Form 4 filing for Zentalis Pharmaceuticals, Inc. (ZNTL).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Feb 2024, 19:13.
Cam Gallagher - 01 Feb 2024 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)
- Reporting relationship
- President, Director
- Issuer ticker
- ZNTL
- Reported as of
- 01 Feb 2024
- Net transaction value
- -$133,310
- SEC form
- 4
- Accepted by SEC
- 05 Feb 2024, 19:13:51 UTC
- Prior SEC filing
- 08 Jun 2023
- Next SEC filing
- 12 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Melissa B. Epperly, Attorney-in-Fact for Cam S. Gallagher
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Cam Gallagher filed Form 4 for Zentalis Pharmaceuticals, Inc. (ZNTL) on 05 Feb 2024.
Change
- Previous filing in this sequence was filed on 08 Jun 2023.
- Current net transaction value: -$133,310.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZNTL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +192,500
- Change %
- +42%
- Price
- $0.000000
- Shares after
- 656,002
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
ZNTL
transaction
Common Stock
Sale
- Transaction value
- $133,310
- Shares
- -11,552
- Change %
- -1.8%
- Price
- $11.54
- Shares after
- 644,450
- Date
- 02 Feb 2024
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZNTL
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +192,500
- Change %
- Price
- $0.000000
- Shares after
- 192,500
- Date
- 01 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 192,500
- Exercise price
- $11.69
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer.
Footnote F2
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units.
Footnote F3
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer.